For a decade, UnicoCell pioneered stem cell therapy R&D. UnicoCell's Gold Award-winning new stem cell product, ELIXCYTE®, has advanced to the case recruitment phase of Phase III clinical trials for knee osteoarthritis and the clinical trial data analysis for phase I/II chronic kidney disease (CKD) has been completed, promising innovative treatments for aging-related diseases. The company follows ICH guidelines, holds a 2022 US FDA Master File (MF) for an adipose-derived stem cell bank, a vital raw material for stem cell drug development. UnicoCell has innovated two patented products: 1. Stem Cell Secretome, which is FDA MF-recognized, and is applied for degenerative eye diseases, regenerative medicine, and exosome research. 2. UnicoVial® ultra-low temperature storage, obtained TFDA Class II medical device approval and FDA MF-recognized, applied for cell therapy and biological product storage. UnicoCell aspires to globalize stem cell technology, promote regenerative medicine for aging-related conditions, and ultimately enhance the quality of human life.